GYBYS(SH:600332)2024-10-25 08:54Financial Performance - The company's operating revenue for Q3 2024 was CNY 18,017,185, a decrease of 1.08% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2024 was CNY 609,412, reflecting a decline of 37.82% year-on-year[3]. - The basic earnings per share for Q3 2024 was CNY 0.375, down 37.82% from the previous year[3]. - The company reported a decrease of 16.68% in net profit attributable to shareholders for the year-to-date period, totaling CNY 3,158,977[3]. - The total profit for Q3 2024 is CNY 4,006,037,802.35, a decrease from CNY 4,752,432,969.83 in Q3 2023, representing a decline of approximately 15.7%[17]. - The net profit attributable to shareholders of the parent company is CNY 3,158,976,998.91, down from CNY 3,791,250,189.92 in the same period last year, reflecting a decrease of about 16.7%[17]. - The basic and diluted earnings per share for Q3 2024 are both CNY 1.943, compared to CNY 2.332 in Q3 2023, indicating a decline of approximately 16.7%[18]. - The company's total profit margin for Q3 2024 is approximately 81.9%, down from 83.5% in Q3 2023, reflecting a decline in profitability[17]. Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was CNY -751,362, representing a significant decrease of 183.33%[3]. - The net cash flow from operating activities for Q3 2024 is negative CNY 751,362,230.20, compared to a positive CNY 901,626,427.54 in Q3 2023[20]. - Cash flow from operating activities for the first nine months of 2024 is CNY 55,018,985,333.25, an increase from CNY 53,474,666,968.88 in the same period of 2023[19]. - The company reported a net cash outflow from investing activities of CNY 4,239,805,542.16 for Q3 2024, compared to a net outflow of CNY 2,209,174,427.17 in Q3 2023[20]. - The company’s cash inflow from financing activities for Q3 2024 is CNY 8,534,366,363.04, compared to CNY 10,798,825,985.69 in Q3 2023, indicating a decrease of approximately 21%[20]. - As of September 30, 2024, the company's cash and cash equivalents amounted to ¥17.19 billion, a decrease of 19.9% from ¥21.31 billion at the end of 2023[12]. - The total cash and cash equivalents at the end of Q3 2024 is CNY 15,424,695,678.20, down from CNY 18,587,127,376.32 at the end of Q3 2023, a decrease of approximately 17.5%[22]. Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 79,255,540, an increase of 0.85% from the end of the previous year[3]. - The company's total assets reached CNY 79,255,540,499.70, compared to CNY 78,586,877,764.09 in the previous year, showing a growth of approximately 0.9%[14]. - Non-current assets totaled CNY 26,205,268,332.03, up from CNY 22,603,164,039.00 year-over-year, marking an increase of about 15.5%[14]. - Total liabilities amounted to CNY 41,202,453,235.03, a slight decrease from CNY 41,909,053,857.29 in the previous year[14]. - Short-term borrowings increased to CNY 9,414,703,611.84 from CNY 7,799,035,643.76, representing a rise of about 20.7%[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 87,322[8]. - The company reported a total of 732,305,103 shares held by Guangzhou Pharmaceutical Group Co., Ltd., representing a significant portion of the free-floating shares[10]. - The top ten shareholders collectively held a significant number of shares, with the largest shareholder holding 732,305,103 shares[10]. - The company has not disclosed any significant changes in the relationships among major shareholders[10]. - There were no significant changes in the borrowing and lending of shares among the top shareholders during the reporting period[10]. Operational Highlights - The company has not reported any new strategies or significant developments in product or technology during the quarter[11]. - The company received government subsidies amounting to CNY 16,371 during the reporting period, contributing to other income[4]. Operating Costs - Total operating revenue for the first three quarters of 2024 reached CNY 59,060,000,304.02, an increase from CNY 58,184,549,516.02 in the same period of 2023, representing a growth of approximately 1.5%[14]. - Total operating costs for the first three quarters of 2024 were CNY 55,409,270,136.71, compared to CNY 53,778,646,989.34 in 2023, indicating an increase of about 3.0%[16]. - Operating profit for the first three quarters of 2024 was CNY 4,001,068,355.99, down from CNY 4,756,262,185.04 in the previous year, reflecting a decrease of approximately 15.9%[16]. Research and Development - Research and development expenses for the first three quarters of 2024 were CNY 578,513,078.86, slightly down from CNY 579,480,533.51 in the same period of 2023[16].